The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial

Journal of Clinical Psychiatry

Volumn 70, Issue 1, 2009, Pages 58-62

  Gandelman, Kuan ^a   Alderman, Jeffrey A ^a   Glue, Paul ^a   Lombardo, Ilise ^a   LaBadie, Robert R ^b   Versavel, Mark ^b   Preskorn, Sheldon H ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIPRASIDONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CALORIE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION URGENCY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIETARY INTAKE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; FAT CONTENT; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; LIPID DIET; LOW CALORY DIET; LOW FAT DIET; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; STEADY STATE; TARDIVE DYSKINESIA; URINE INCONTINENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIPOLAR DISORDER; CROSS-OVER STUDIES; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; ENERGY INTAKE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES; YOUNG ADULT;

EID: 60349093506     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04104     Document Type: Article

References (10)

1. Harvey PD, Bowie CR. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother 2005;6(2):337-346
2. Patel NC, Keck PE Jr. Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Rev Neurother 2006;6(8):1129-1138
3. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(suppl 1):5S-13S
4. Geodon [prescribing information]. New York, NY: Pfizer Inc; 2007
5. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 1998;18(1):9-15
6. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, Md: US Dept of Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2002
7. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227-235
8. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161(5):818-825
9. Miceli JJ, Glue P, Alderman J, et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 2007;40(3):58-68
10. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42(6):620-643